FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to oncology, and can be used for screening of breast cancer and predisposition to it. A mammography and an ultrasonography are performed. That is combined with radiothermometric examination of the mammary glands and separating a micro-RNA panel from biological fluids containing miR-199a, miR-222, let-7a, miR-196a, miR-106a, miR-21, miR-137, miR-155.
EFFECT: method enables to isolate a group of breast pathologies from the mass of dyshormonal diseases of the mammary glands, which in the foreseeable future will turn into cancer, due to combined use of radio thermometry and a micro-RNA panel.
1 cl, 1 dwg, 2 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DIAGNOSTICS AND TREATMENT OF OBLIGATE PRECANCER DISEASES AND CA IN SITU | 2021 |
|
RU2794856C2 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF OVARIAN CANCER, OVARIAN CYSTIC GROWTHS AND UTERINE CANCER | 2024 |
|
RU2836527C1 |
| ONCOLYTIC VIRAL VECTORS AND USE THEREOF | 2017 |
|
RU2749050C2 |
| METHOD FOR PREDICTING RECURRENCE OF SEROUS OVARIAN CARCINOMA | 2020 |
|
RU2749361C1 |
| METHOD OF DIFFERENTIAL DIAGNOSIS OF PROSTATE CANCER AND BENIGN PROSTATIC HYPERPLASIA | 2016 |
|
RU2646790C1 |
| METHOD FOR DIAGNOSING GLIAL BRAIN TUMORS OF HIGH DEGREE OF MALIGNANCY | 2020 |
|
RU2742413C1 |
| METHOD OF DIFFERENTIAL DIAGNOSIS OF PROSTATE CANCER AND BENIGN PROSTATIC HYPERPLASIA | 2016 |
|
RU2647433C1 |
| METHOD FOR DIAGNOSING BREAST CANCER BY LEVEL OF MRNA TGEβ AND TNFα IN BLOOD PLASMA | 2019 |
|
RU2742209C1 |
| METHOD FOR NON-INVASIVE SEMI-QUANTITATIVE ASSESSMENT OF VIABILITY OF MDA-MB-231 CELLS IN MULTIORGAN MICROPHYSIOLOGICAL MODELS | 2020 |
|
RU2752426C2 |
| RECOMBINANT PLASMID DNA CODING microRNA hsa-miR-143-5p, AND ITS USE AS POSITIVE CONTROL IN REAL-TIME PCR FOR DIAGNOSING CARDIOVASCULAR DISEASES AND DETECTING RISK OF THEIR DEVELOPMENT | 2025 |
|
RU2837872C1 |
